Medicine Questions
Report an Adverse Event
Investors
Contact
North America South America
Asia
Middle East Africa Australia
Europe

Pipeline

Last Updated Date: October 27, 2022

The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

60

Clinical Stage Programs1                                                        

10

Potential clinical stage opt-in assets

1 Program count does not include potential partner opt-in programs or publicly announced planned programs.

On this page

Viral Diseases

Inflammatory Diseases

Oncology

Pack of testing vials laid out inside a Gilead laboratory

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities unless otherwise noted.

Viral Diseases

Emerging Viruses

  • Novel oral COVID-19 nucleoside (GS-5245)

    COVID-19

    PHASE 1

HIV

  • Lenacapavir (CAPELLA)1

    Long acting HIV treatment for heavily treatment experienced people living with HIV

    FILED NDA
  • Lenacapavir (PURPOSE 1 & 2)

    HIV PrEP

    PHASE 3
  • Lenacapavir / bictegravir oral combination (ARTISTRY-1)

    Long acting HIV treatment for virologically suppressed people living with HIV

    PHASE 2/3
  • Lenacapavir1

    Long acting HIV treatment for virologically suppressed people living with HIV

    PHASE 2
  • Lenacapavir/islatravir oral combination3

    Long acting HIV treatment for virologically suppressed people living with HIV

    PHASE 2
  • bNAb combination (GS-5423, GS-2872)4

    HIV cure

    PHASE 2
  • Lefitolimod4

    HIV cure

    PHASE 2
  • Vesatolimod4

    HIV cure

    PHASE 2
  • Therapeutic vaccines5

    HIV cure

    PHASE 1
  • Lenacapavir / bNAb combination

    Long acting HIV treatment for virologically suppressed people living with HIV

    PHASE 1
  • Long acting INSTI (GS-6212)

    Long acting HIV treatment

    PHASE 1
  • HIV NNRTI (GS-5894)

    Long acting HIV treatment

    PHASE 1

HBV and HDV

  • Hepcludex® (MYR301)6,7

    HDV

    FILED BLA
  • Bulevirtide (MYR301, MYR204)

    HDV Finite Treatment

    PHASE 3
  • Selgantolimod

    HBV cure

    PHASE 2

1 Breakthrough therapy designation.

2 Phase 2 study being conducted in treatment naïve patients to support virologically suppressed indication.

3 Subject to Gilead and Merck co-development and co-commercialization agreement.

4 Non-Gilead sponsored trial(s) ongoing.

5 Clinical collaboration with Gritstone

6 Conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.

7 Breakthrough and PRIME designations.

bNAb – Broadly neutralizing antibody
CoV – Coronavirus
HBV – Hepatitis B virus
HDV – Hepatitis delta virus
HIV – Human immunodeficiency virus
INSTI – Integrase strand transfer inhibitor
NNRTI – Non-nucleoside reverse transcriptase inhibitor
PrEP – Pre-exposure prophylaxis

Inflammatory Diseases

  • TPL2 inhibitor (GS-5290)

    Inflammatory bowel disease

    PHASE 1
  • IRAK4 inhibitor (GS-5718)

    Inflammatory bowel disease

    PHASE 1
  • IRAK4 inhibitor (GS-5718)

    Rheumatoid arthritis

    PHASE 1
  • IRAK4 inhibitor (GS-5718)1

    Lupus

    PHASE 1
  • α4β7 inhibitor (GS-1427)

    Inflammatory bowel disease

    PHASE 1
  • BTLA agonist (GS-0272)

    Inflammatory diseases

    PHASE 1

Fibrotic Diseases

  • Cilofexor / firsocostat / semaglutide combination2

    Nonalcoholic steatohepatitis

    PHASE 2

Potential Opt-in Programs

Galapagos

Inflammatory and fibrotic diseases
3 clinical stage programs

1 Screening/enrollment paused pending evaluation of preliminary preclinical findings.

2 Clinical collaboration with Novo Nordisk.

BTLA – B- and T-lymphocyte attenuator
IRAK4 – Interleukin 1 receptor associated kinase 4
TPL2 – Tumor progression locus 2

 

Oncology

  • Sacituzumab govitecan-hziy (TROPiCS-02)

    Hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer 

    FILED sBLA
  • Trodelvy® (TROPiCS-04)

    2L metastatic urothelial carcinoma

    PHASE 3
  • Sacituzumab govitecan-hziy (EVOKE-01)

    2-3L non small cell lung cancer

    PHASE 3
  • Sacituzumab govitecan-hziy (ASCENT-03)

    1L metastatic triple-negative breast cancer (PD-L1-)

    PHASE 3
  • Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-04)1

    1L metastatic triple-negative breast cancer (PD-L1+)

    PHASE 3
  • Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-03)1,2

    1L non small cell lung cancer

    PHASE 3
  • Magrolimab + azacitidine (ENHANCE)3,4

    1L higher risk myelodysplastic syndrome

    PHASE 3
  • Magrolimab + azacitidine (ENHANCE-2)4

    1L TP53m acute myeloid leukemia

    PHASE 3
  • Magrolimab + venetoclax + azacitidine (ENHANCE-3)

    1L unfit acute myeloid leukemia

    PHASE 3
  • Domvanalimab + zimberelimab (ARC-10)5

    1L non small cell lung cancer

    PHASE 3
  • Domvanalimab + durvalumab (PACIFIC-8)6

    Stage 3 non small cell lung cancer

    PHASE 3
  • Domvanalimab + zimberelimab + chemotherapy (STAR-121)2,5

    1L non small cell lung cancer

    PHASE 3
  • Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-02)1

    1L non small cell lung cancer

    PHASE 2
  • Sacituzumab govitecan-hziy + combinations (TROPHY-U-01)

    1L metastatic urothelial carcinoma

    PHASE 2
  • Sacituzumab govitecan-hziy (TROPiCS-03)

    Basket (Solid tumors)

    PHASE 2
  • Magrolimab + chemotherapy/IO combinations

    Head and neck squamous cell carcinoma

    PHASE 2
  • Magrolimab + chemotherapy

    Solid tumors

    PHASE 2
  • Magrolimab combinations

    Multiple myeloma

    PHASE 2
  • Magrolimab + chemotherapy/SG combinations

    Triple-negative breast cancer

    PHASE 2
  • Magrolimab combinations

    Metastatic colorectal cancer

    PHASE 2
  • Domvanalimab + zimberelimab + etrumadenant (ARC-7)5

    Non small cell lung cancer

    PHASE 2
  • Quemliclustat + zimberelimab (ARC-8)5

    Metastatic pancreatic ductal adenocarcinoma

    PHASE 2
  • Etrumadenant + zimberelimab combinations (ARC-9)5

    Metastatic colorectal cancer

    PHASE 2
  • Domvanalimab + zimberelimab + chemotherapy (ARC-21)5

    1-2L upper GI cancer

    PHASE 2
  • Etrumadenant + zimberelimab combinations (ARC-6)5

    Metastatic castrate-resistant prostate cancer

    PHASE 1b/2
  • Magrolimab anti-CD47 (GS-4721)

    Magrolimab combinations

    PHASE 1b/2
  • AB308 + zimberelimab (ARC-12)5

    Advanced cancers

    PHASE 1b
  • Flt3R agonist (GS-3583)

    Advanced cancers

    PHASE 1b
  • CCR8 (GS-1811)

    Advanced cancers

    PHASE 1a
  • MCL1 inhibitor (GS-9716)

    Advanced cancers

    PHASE 1a

Cell Therapy

  • Axicabtagene ciloleucel (ZUMA-22)

    2L+ high-risk follicular lymphoma

    PHASE 3
  • Axicabtagene ciloleucel (ZUMA-23)2

    1L high-risk large B-cell lymphoma

    PHASE 3
  • Axicabtagene ciloleucel (ZUMA-24)

    2L large B-cell lymphoma outpatient

    PHASE 2
  • Axicabtagene ciloleucel (ZUMA-12)

    1L large B-cell lymphoma

    PHASE 2
  • Brexucabtagene autoleucel (ZUMA-4)

    Pediatric acute lymphocytic leukemia

    PHASE 2 Pivotal
  • Brexucabtagene autoleucel (ZUMA-25)2

    Basket (rare B-cell malignancies)

    PHASE 2
  • CLL-1 (KITE-222)

    Relapsed/refractory acute myeloid leukemia

    PHASE 1
  • CD19/20 bicistronic (KITE-363)

    3L+ diffuse large B-cell lymphoma

    PHASE 1

Potential Opt-in Programs

Pionyr

Advanced cancers
2 clinical stage programs

Agenus

Advanced cancers
1 clinical stage program

Arcus

Advanced cancers
1 clinical stage program

Tizona

Advanced cancers
1 clinical stage program

MacroGenics

Advanced cancers
1 clinical stage program

Galapagos

Advanced cancers
1 clinical stage program

1 In collaboration with Merck.

2 Publicly announced planned program (non-exhaustive).

3 Breakthrough and PRIME designations and Promising Innovative Medicine from MHRA.

4 Additional MDS and AML cohorts within other ongoing Phase 1b study. 

5 In collaboration with Arcus Biosciences.

6 In collaboration with Arcus Biosciences and AstraZeneca. 

GI – Gastrointestinal
IO – Immuno-oncology
MCL1 – myeloid cell leukemia-1
PD-L1 – Programmed death-ligand 1
SG - Sacituzumab govitecan-hziy
TP53m – Tumor protein 53 mutation

Some of the content on this page is not intended for users outside the United States.